Methods for providing effective reboxetine therapy with once-a-day dosing

US6630165B2 · kind B2 · utility

Assignee

• ALZA CORPORATION · US

Inventors

• Sylvia Seroff · Sunnyvale, US
• Noymi Yam · Sunnyvale, US
• Atul D. Ayer · Palo Alto, US
• Padmanabh P. Bhatt · Rockville, US
• Michael A. Desjardin · Sunnyvale, US
• Andrew Lam · South San Francisco, US
• David E. Edgren · El Granada, US
• Phillip Nixon · Portage, US

Key dates

• Filing date: Feb 28, 2002
• Grant date: Oct 7, 2003
• Expiry date: Feb 28, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.